Sökning: id:"swepub:oai:DiVA.org:liu-199831" >
Antitumor T-cell Ho...
-
Marshall, NetoniaDepartment of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine, Mount Sinai Hospital, New York, USA
(författare)
Antitumor T-cell Homeostatic Activation Is Uncoupled from Homeostatic Inhibition by Checkpoint Blockade
- Artikel/kapitelEngelska2019
Förlag, utgivningsår, omfång ...
-
2019-11-01
-
American Association For Cancer Research (AACR),2019
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:liu-199831
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-199831URI
-
https://doi.org/10.1158/2159-8290.cd-19-0391DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
T-cell transfer into lymphodepleted recipients induces homeostatic activation and potentiates antitumor efficacy. In contrast to canonical T-cell receptor–induced activation, homeostatic activation yields a distinct phenotype and memory state whose regulatory mechanisms are poorly understood. Here, we show in patients and murine models that, following transfer into lymphodepleted bone marrow transplant (BMT) recipients, CD8+ T cells undergo activation but also simultaneous homeostatic inhibition manifested by upregulation of immune-checkpoint molecules and functional suppression. T cells transferred into BMT recipients were protected from homeostatic inhibition by PD-1/CTLA4 dual checkpoint blockade (dCB). This combination of dCB and BMT— ”immunotransplant”—increased T-cell homeostatic activation and antitumor T-cell responses by an order of magnitude. Like homeostatic activation, homeostatic inhibition is IL7/IL15-dependent, revealing mechanistic coupling of these two processes. Marked similarity in ex vivo modulation of post-BMT T cells in mice and patients is promising for the clinical translation of immunotransplant (NCT03305445) and for addressing homeostatic inhibition in T-cell therapies. SIGNIFICANCE: For optimal anticancer effect, T-cell therapies including chimeric antigen receptor T-cell, tumor-infiltrating lymphocyte, and transgenic T-cell therapies require transfer into lymphodepleted recipients and homeostatic activation; however, concomitant homeostatic inhibition mitigates T-cell therapies’ efficacy. Checkpoint blockade uncouples homeostatic inhibition from activation, amplifying T-cell responses. Conversely, tumors nonresponsive to checkpoint blockade or BMT are treatable with immunotransplant. © 2019 American Association for Cancer Research.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Hutchinson, KeinoDepartment of Pharmacological Sciences, Icahn School of Medicine, Mount Sinai Hospital, New York, USA
(författare)
-
Marron, Thomas U.Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine, Mount Sinai Hospital, New York, USA
(författare)
-
Aleynick, MarkDepartment of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine, Mount Sinai Hospital, New York, USA
(författare)
-
Hammerich, LindaDepartment of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine, Mount Sinai Hospital, New York, USA
(författare)
-
Upadhyay, Ranjan1Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine, Mount Sinai Hospital, New York, New York.
(författare)
-
Svensson-Arvelund, Judit,1982-Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine, Mount Sinai Hospital, New York, USA(Swepub:liu)judsv82
(författare)
-
Brown, Brian D.Department of Genetics and Genomic Sciences, Icahn School of Medicine, Mount Sinai Hospital, New York, USA
(författare)
-
Merad, MiriamDepartment of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine, Mount Sinai Hospital, New York, New York.;4Department of Oncological Sciences, Icahn School of Medicine, Mount Sinai Hospital, New York, USA
(författare)
-
Brody, Joshua D.1Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine, Mount Sinai Hospital, New York, New York.
(författare)
-
Department of Medicine, Division of Hematology and Medical Oncology, Icahn School of Medicine, Mount Sinai Hospital, New York, USADepartment of Pharmacological Sciences, Icahn School of Medicine, Mount Sinai Hospital, New York, USA
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Cancer Discovery: American Association For Cancer Research (AACR)9:11, s. 1520-15372159-82742159-8290
Internetlänk
Hitta via bibliotek
Till lärosätets databas